Business Context and Reporting Period
This Form 6-K filing by Embraer S.A. covers the month of June 2019. The report details a specific commercial transaction announced on June 18, 2019, at the 53rd International Paris Air Show, rather than providing comprehensive quarterly financial results.
Key Financial Metrics
- New Order Value: USD 97.2 million (based on 2019 list prices).
- Order Composition: Firm order for two E175 jets.
- Backlog Status: The order was already included in Embraer's first-quarter 2019 backlog as "undisclosed."
- Revenue/Profit/Cash Flow: The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity for the reporting period.
Material Changes and Operational Updates
- Customer Expansion: Fuji Dream Airlines (FDA), a Japanese carrier, ordered two additional E175 aircraft to expand its all-Embraer fleet.
- Fleet Configuration: The new aircraft will feature a single-class layout with 84 seats, with deliveries scheduled to begin in 2019.
- Service Agreement: FDA and Embraer signed an extension of the Pool Program covering the airline's E170 and E175 fleet, including advance exchange and repair management for over 300 line replacement units.
- Market Position: The E175 remains the best-seller of the E-Jets family with over 770 global orders. Since January 2013, Embraer has sold over 565 E175s in North America alone.
Management Commentary and Outlook
Embraer management highlighted the strategic importance of the Asia Pacific region, noting that a total of 48 E-Jets will be flying in Japan by the end of 2019. Cesar Pereira, Asia Pacific Vice President, emphasized FDA's 99.83% dispatch reliability as a testament to Embraer's product quality and support standards. The company continues to position itself as the world's leading manufacturer of commercial aircraft up to 150 seats.
Investor Verification Checklist
- Verify the impact of the USD 97.2 million order on the total backlog reported in the subsequent quarterly earnings release.
- Confirm the delivery schedule for the two E175s to ensure alignment with the "starting in 2019" timeline.
- Review the terms of the extended Pool Program to assess potential recurring service revenue implications.
- Monitor FDA's operational performance and route expansion plans as a leading indicator for regional demand in Asia.